Unknown

Dataset Information

0

Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.


ABSTRACT:

SUBMITTER: Chen XQ 

PROVIDER: S-EPMC7984396 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.

Chen Xu-Qiao XQ   Salehi Ahmad A   Pearn Matthew L ML   Overk Cassia C   Nguyen Phuong D PD   Kleschevnikov Alexander M AM   Maccecchini Maria M   Mobley William C WC  

Alzheimer's & dementia : the journal of the Alzheimer's Association 20200925 2


<h4>Objective</h4>Recent clinical trials targeting amyloid beta (Aβ) and tau in Alzheimer's disease (AD) have yet to demonstrate efficacy. Reviewing the hypotheses for AD pathogenesis and defining possible links between them may enhance insights into both upstream initiating events and downstream mechanisms, thereby promoting discovery of novel treatments. Evidence that in Down syndrome (DS), a population markedly predisposed to develop early onset AD, increased APP gene dose is necessary for bo  ...[more]

Similar Datasets

| S-EPMC4919106 | biostudies-literature
| S-EPMC3096739 | biostudies-literature
| S-EPMC3254042 | biostudies-literature
| S-EPMC10592033 | biostudies-literature
| S-EPMC11668655 | biostudies-literature
| S-EPMC6021259 | biostudies-literature
| S-EPMC3259223 | biostudies-literature
| S-EPMC3389345 | biostudies-literature
| S-EPMC9094519 | biostudies-literature
| S-EPMC9470680 | biostudies-literature